secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2025-07-03T23:59:59+00:00
Accession:  0001193125-25-155503
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

UroGen awards special bonuses totaling $845K to CEO, CFO, GC for ZUSDURI FDA approval
--------------------------------------------------------------------------------

- CEO Elizabeth Barrett receives $645,000; CFO Chris Degnan and GC Jason Smith each get $100,000.
- Bonuses approved June 30, 2025, for leadership leading to FDA approval of ZUSDURI for recurrent low-grade intermediate risk NMIBC.
- ZUSDURI is a novel therapy for non-muscle invasive bladder cancer (NMIBC).
- One-time special awards; no recurrence or changes to base compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312525155503/0001193125-25-155503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312525155503/d941822d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-155503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer